Fidelity Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
Sell
-10,207
Closed -$18.9K 5678
2023
Q1
$18.9K Sell
10,207
-67,591
-87% -$83.7K ﹤0.01% 3864
2022
Q4
$86.4K Sell
77,798
-766,989
-91% -$1.09M ﹤0.01% 3265
2022
Q3
$1.98M Sell
844,787
-421,024
-33% -$1.49M ﹤0.01% 2428
2022
Q2
$3.83M Buy
1,265,811
+1,158,847
+1,083% +$5.64M ﹤0.01% 2316
2022
Q1
$726K Sell
106,964
-238,667
-69% -$1.7M ﹤0.01% 2867
2021
Q4
$2.89M Sell
345,631
-445,303
-56% -$3.67M ﹤0.01% 2482
2021
Q3
$5.88M Hold
790,934
﹤0.01% 2313
2021
Q2
$5.38M Buy
790,934
+49,900
+7% +$415K ﹤0.01% 2310
2021
Q1
$7.61M Buy
741,034
+623,260
+529% +$6.83M ﹤0.01% 2138
2020
Q4
$824K Sell
117,774
-45,100
-28% -$351K ﹤0.01% 2564
2020
Q3
$1.33M Sell
162,874
-401,100
-71% -$2.49M ﹤0.01% 2376
2020
Q2
$3.89M Hold
563,974
﹤0.01% 2118
2020
Q1
$2.68M Sell
563,974
-674,800
-54% -$3.88M ﹤0.01% 2120
2019
Q4
$10.8M Buy
1,238,774
+500,600
+68% +$2.71M ﹤0.01% 1818
2019
Q3
$2.46M Sell
738,174
-181,403
-20% -$726K ﹤0.01% 2223
2019
Q2
$4.55M Sell
919,577
-87,297
-9% -$464K ﹤0.01% 2119
2019
Q1
$6.24M Sell
1,006,874
-241
-0% -$1.16K ﹤0.01% 2010
2018
Q4
$3.39M Sell
1,007,115
-1,197,332
-54% -$5.59M ﹤0.01% 2152
2018
Q3
$14.3M Sell
2,204,447
-737,885
-25% -$5.49M ﹤0.01% 1822
2018
Q2
$22.5M Sell
2,942,332
-30,000
-1% -$433K ﹤0.01% 1669
2018
Q1
$66.4M Buy
2,972,332
+343,942
+13% +$7.63M 0.01% 1167
2017
Q4
$33.5M Sell
2,628,390
-644,036
-20% -$9.47M ﹤0.01% 1483
2017
Q3
$51M Sell
3,272,426
-699,590
-18% -$9.89M 0.01% 1298
2017
Q2
$53.6M Sell
3,972,016
-74,300
-2% -$1.59M 0.01% 1266
2017
Q1
$82.4M Buy
+4,046,316
New +$85.7M 0.01% 1073

Other funds holding JNCE

Fidelity Investments's JNCE Position: Q2 2023 in Review

Fidelity Investments sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2023, closing a stake of 10,207 shares — an estimated $18.9K sold.

Fidelity Investments first reported a position in JNCE in Q1 2017 and held it in 25 quarters. The position peaked at $82.4M in Q1 2017. 1 fund tracked by Wall St. Rank holds JNCE as of Q2 2023.

  • Fidelity Investments reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Fidelity Investments sold 10,207 Jounce Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $18.9K.
  • Fidelity Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2017 and held it in 25 quarters.
  • Fidelity Investments's Jounce Therapeutics, Inc. Common Stock position peaked at $82.4M in Q1 2017.
  • 1 fund tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Fidelity Investments's 13F filing for Q2 2023, filed 11 Aug 2023.